Induced pluripotent stem cells (iPSCs) provide a powerful starting material to model human disease in relevant cell types. iPSCs may be generated from patients of any genetic background and possess the capacity to differentiate into almost any desired terminal cell type.

Although additional investigation is needed, researchers are beginning to focus on the potential utility of iPSCs as a tool for drug development, modeling of disease, and transplantation medicine.

Using ATCCs complete feeder- and xeno-free culture systems, researchers can generate standardized, quality controlled, and highly characterized human iPSCs lines. ATCCs iPSCs are derived by episomal, retroviral, or Sendai viral reprogramming. After gaining pluripotent status, the iPSCs may then be induced to differentiate into many cell types. These cells are valuable materials in the study of differentiation, tissue repair, disease pathogenesis, and drug discovery and development.

ATCC is a licensee of iPS Academia Japans induced pluripotent stem (iPS) cell patent portfolio and is able to bring complete cell culturing solutions for iPSCs to the research community.

ATCC iPSCs are tested for pluripotency, karyotype, growth potential, and sample purity. These authenticated materials are backed by meticulous quality control procedures, making them ideal as reference standards for physiologically relevant in vitro research.

View post:
Human Induced Pluripotent Stem Cells | ATCC